Imprimis Pharmaceuticals, Inc. (Imprimis) is a pharmaceutical company. The Company focuses on developing and commercializing compounded drug therapies and making these therapies available to physicians and patients. It owns, markets and sells a portfolio of combination formulations in ophthalmology and urology. Its ophthalmology formulation portfolio includes Dropless Therapy and LessDrops formulations, which serve the eye drop market. Its Defeat IC campaign includes a compounded formulation for patients suffering from interstitial cystitis. It makes, dispenses and sells its compounded formulations, as well as other